|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0031184,
umls-concept:C0033371,
umls-concept:C0036667,
umls-concept:C0040223,
umls-concept:C0057223,
umls-concept:C0312418,
umls-concept:C0750729,
umls-concept:C0871261,
umls-concept:C1332830,
umls-concept:C1333253,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1709518,
umls-concept:C2911692
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-12-13
|
|
pubmed:abstractText |
We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. As genetic heterogeneity in drug targets can influence drug response, we sought to further evaluate the contribution of CYP2D6 to pharmacodynamic sensitivity in our previous study sample in tandem with DRD2, the primary molecular target for perphenazine.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1744-6872
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
989-93
|
|
pubmed:meshHeading |
pubmed-meshheading:18075468-Antipsychotic Agents,
pubmed-meshheading:18075468-Area Under Curve,
pubmed-meshheading:18075468-Cytochrome P-450 CYP2D6,
pubmed-meshheading:18075468-Double-Blind Method,
pubmed-meshheading:18075468-Genotype,
pubmed-meshheading:18075468-Humans,
pubmed-meshheading:18075468-Perphenazine,
pubmed-meshheading:18075468-Pituitary Gland,
pubmed-meshheading:18075468-Polymorphism, Genetic,
pubmed-meshheading:18075468-Prolactin,
pubmed-meshheading:18075468-Receptors, Dopamine D2,
pubmed-meshheading:18075468-Taq Polymerase,
pubmed-meshheading:18075468-Time Factors
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
|
|
pubmed:affiliation |
Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska University Hospital-Huddinge, Karolinska Institutet, Stockholm, Sweden.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
